Document Detail


A personalized treatment for lung cancer: molecular pathways, targeted therapies, and genomic characterization.
MedLine Citation:
PMID:  24292963     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Lung cancer is a heterogeneous, complex, and challenging disease to treat. With the arrival of genotyping and genomic profiling, our simple binary division of lung cancer into non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) is no longer acceptable. In the past decade and with the advent of personalized medicine, multiple advances have been made in understanding the underlying biology and molecular mechanisms of lung cancer. Lung cancer is no longer considered a single disease entity and is now being subdivided into molecular subtypes with dedicated targeted and chemotherapeutic strategies. The concept of using information from a patient's tumor to make therapeutic and treatment decisions has revolutionized the landscape for cancer care and research in general.Management of non-small-cell lung cancer, in particular, has seen several of these advances, with the understanding of activating mutations in EGFR, fusion genes involving ALK, rearrangements in ROS-1, and ongoing research in targeted therapies for K-RAS and MET. The next era of personalized treatment for lung cancer will involve a comprehensive genomic characterization of adenocarcinoma, squamous-cell carcinoma, and small-cell carcinoma into various subtypes. Future directions will involve incorporation of molecular characteristics and next generation sequencing into screening strategies to improve early detection, while also having applications for joint treatment decision making in the clinics with patients and practitioners. Personalization of therapy will involve close collaboration between the laboratory and the clinic. Given the heterogeneity and complexity of lung cancer treatment with respect to histology, tumor stage, and genomic characterization, mind mapping has been developed as one of many tools which can assist physicians in this era of personalized medicine. We attempt to utilize the above tool throughout this chapter, while reviewing lung cancer epidemiology, lung cancer treatment, and the genomic characterization of lung cancer.
Authors:
Thomas Hensing; Apoorva Chawla; Rishi Batra; Ravi Salgia
Related Documents :
20619523 - Jade and the journalists: media coverage of a young british celebrity dying of cancer.
24984283 - Association of melanoma with intraepithelial neoplasia of pancreas in three patients.
24254203 - Mechanistic background and clinical applications of indocyanine green fluorescence imag...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Advances in experimental medicine and biology     Volume:  799     ISSN:  0065-2598     ISO Abbreviation:  Adv. Exp. Med. Biol.     Publication Date:  2014  
Date Detail:
Created Date:  2013-12-02     Completed Date:  2014-04-18     Revised Date:  2014-04-29    
Medline Journal Info:
Nlm Unique ID:  0121103     Medline TA:  Adv Exp Med Biol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  85-117     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenocarcinoma* / drug therapy,  genetics,  metabolism,  pathology
Carcinoma, Non-Small-Cell Lung* / drug therapy,  genetics,  metabolism,  pathology
Carcinoma, Small Cell* / drug therapy,  genetics,  metabolism,  pathology
Drug Delivery Systems / methods*
Humans
Individualized Medicine / methods*,  trends
Lung Neoplasms* / drug therapy,  genetics,  metabolism,  pathology
Neoplasm Proteins* / genetics,  metabolism
Small Cell Lung Carcinoma* / drug therapy,  genetics,  metabolism,  pathology
Grant Support
ID/Acronym/Agency:
T32 CA009566/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Neoplasm Proteins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Computational approaches for human disease gene prediction and ranking.
Next Document:  Rejection and Victimization among Elementary School Children: The Buffering Role of Classroom-Level ...